GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF

1 . A compound of Formula (A):

or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

X is N or CH;

R is H, NH 2 , or NHCH 3 ;

is a single bond or a double bond;

Y 1 is N or CR 1 ; Y 2 is N or CR 2 , Y 3 is N or CR 3 ; and Y 4 is N or CR 4 ;

Z 1 is N or CR 5 ; Z 2 is N or CR 6 ; Z 3 is N or CR 7 ; Z 4 is N or CR 8 ; and Z 5 is N or CR 9 ;

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 2 -C 6 alkenyl, unsubstituted or substituted C 2 -C 6 alkynyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, unsubstituted or substituted 4- to 6-membered heterocycloalkyl, —CN, —OR 10 , —CO 2 R 10 , —C(═O)N(R 10 ) 2 , —N(R 10 ) 2 , —NR 1 C(═O)R 11 , —SR 10 , —S(═O)R 11 , —SO 2 R 11 , —SO 2 N(R 10 ) 2 , or —N(R 10 )SO 2 R 11 ;

each R 10 is independently selected from hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, 4- to 6-membered heterocycloalkyl;

or two R 10 on the same N atom are taken together with the N atom to which they are attached to form an unsubstituted or substituted N-containing 4- to 6-membered heterocycloalkyl; and

each R 11 is independently selected from unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, 4- to 6-membered heterocycloalkyl;

wherein each substituted alkyl, substituted alkenyl, substituted alkynyl, substituted fluoroalkyl, substituted heteroalkyl, substituted cycloalkyl, and substituted heterocycloalkyl is substituted with one or more R s groups independently selected from the group consisting of halogen, C 1 -C 6 alkyl, monocyclic carbocycle, monocyclic heterocycle, —CN, —OR 12 , —CO 2 R 12 , —C(═O)N(R 12 ) 2 , —N(R 12 ) 2 , —NR 12 C(═O)R 13 , —SR 12 , —S(═O)R 13 , —SO 2 R 13 , —SO 2 N(R 12 ) 2 , or —N(R 12 )SO 2 R 13 ;

each R 12 is independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5-membered heteroaryl and 6-membered heteroaryl; or two R 12 groups are taken together with the N atom to which they are attached to form a N-containing 4- to 6-membered heterocycloalkyl;

each R 13 is independently selected from C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5-membered heteroaryl and 6-membered heteroaryl;

wherein 0, 1, or 2 of Y 1 , Y 2 , Y 3 , and Y 4 are N; and

wherein 0, 1, or 2 of Z 1 , Z 2 , Z 3 , Z 4 , and Z 5 are N.

2 . The compound of claim 1 , wherein the compound is a compound of Formula (A1):

or a pharmaceutically acceptable salt, or solvate thereof.

3 . The compound of claim 1 , wherein the compound is a compound of Formula (A2):

or a pharmaceutically acceptable salt, or solvate thereof.

4 . The compound of any one of claims 1 - 3 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

0 or 1 of Y 1 , Y 2 , Y 3 , and Y 4 is N.

5 . The compound any one of claims 1 - 4 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

0 or 1 of Z 1 , Z 2 , Z 3 , Z 4 , and Z 5 is N.

6 . The compound of any one of claims 1 - 5 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

0 or 1 of Y 1 , Y 2 , Y 3 , and Y 4 is N; and

0 or 1 of Z 1 , Z 2 , Z 3 , Z 4 , and Z 5 is N.

7 . The compound of claim 1 , wherein the compound is a compound of Formula (B):

or a pharmaceutically acceptable salt, or solvate thereof.

8 . The compound of claim 7 , wherein the compound is a compound of Formula (B1):

or a pharmaceutically acceptable salt, or solvate thereof.

9 . The compound of claim 7 , wherein the compound is a compound of Formula (B2):

or a pharmaceutically acceptable salt, or solvate thereof.

10 . The compound of claim 1 , wherein the compound is a compound of Formula (C):

or a pharmaceutically acceptable salt, or solvate thereof.

11 . The compound of claim 10 , wherein the compound is a compound of Formula (C1):

or a pharmaceutically acceptable salt, or solvate thereof.

12 . The compound of claim 10 , wherein the compound is a compound of Formula (C2):

or a pharmaceutically acceptable salt, or solvate thereof.

13 . The compound of any one of claims 1 - 12 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

14 . The compound of any one of claims 1 - 13 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

15 . The compound of any one of claims 1 - 14 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

16 . The compound of claim 11 , wherein the compound is a compound of Formula (C1-a) or Formula (C1-c):

or a pharmaceutically acceptable salt, or solvate thereof.

17 . The compound of any one of claims 1 - 12 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

18 . The compound of claim 17 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

X is N.

19 . The compound of claim 17 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

X is CH.

20 . The compound of any one of claims 17 - 19 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R is NH 2 .

21 . The compound of any one of claims 17 - 19 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R is H.

22 . The compound of claim 17 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

23 . The compound of claim 17 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

M is

24 . The compound of claim 11 , wherein the compound is a compound of Formula (C1-o):

or a pharmaceutically acceptable salt, or solvate thereof.

25 . The compound of claim 12 , wherein the compound is a compound of Formula (C2-o) or (C2-p):

or a pharmaceutically acceptable salt, or solvate thereof.

26 . The compound of any one of claims 1 - 25 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , and R 9 are each independently hydrogen, halogen, —CN, —OR 10 , —N(R 10 ) 2 , C 1 -C 6 alkyl, or C 1 -C 6 fluoroalkyl.

27 . The compound of any one of claims 1 - 26 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , and R 9 are each independently hydrogen, —F, —Cl, —CN, —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 OCH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CHF 2 , or —CF 3 .

28 . The compound of any one of claims 1 - 27 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , and R 9 are each independently hydrogen, —F, or —CH 3 .

29 . The compound of claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound is a compound of Formula (D):

or a pharmaceutically acceptable salt, or solvate thereof; wherein:

R 2 and R 7 are each independently hydrogen, halogen, —CN, —OR 10 , —N(R 10 ) 2 , C 1 -C 6 alkyl, or C 1 -C 6 fluoroalkyl.

30 . The compound of claim 29 , wherein the compound is a compound of Formula (D1):

or a pharmaceutically acceptable salt, or solvate thereof.

31 . The compound of claim 29 , wherein the compound is a compound of Formula (D2):

or a pharmaceutically acceptable salt, or solvate thereof.

32 . The compound of any one of claims 29 - 31 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R 2 is hydrogen, —F, —Cl, —CN, —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 OCH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CHF 2 , or —CF 3 ;

R 7 is hydrogen, —F, —Cl, —CN, —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 OCH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CHF 2 , or —CF 3 .

33 . The compound of any one of claims 29 - 32 , or a pharmaceutically acceptable salt, or solvate thereof, wherein:

R 2 is hydrogen, —F, or —CH 3 ;

R 7 is hydrogen, —F, —Cl, —CN, —OCH 3 , —OCH 2 CH 2 OCH 3 , or —NH 2 .

34 . The compound of claim 1 , selected from:

or a pharmaceutically acceptable salt, or solvate thereof.

35 . A pharmaceutical composition comprising the compound of any one of claims 1 - 34 , or a pharmaceutically acceptable salt, or solvate thereof, and a pharmaceutically acceptable excipient.

36 . A method of treating a disease of condition amenable to treatment with a glutaminyl-peptide cyclotransferase like (QPCTL) inhibitor, the method comprising administering a compound of any one of claims 1 - 34 , or a pharmaceutically acceptable salt, or solvate thereof to a subject in need thereof, or the pharmaceutical composition of claim 35 .

37 . The method of claim 36 , wherein the disease or condition is a cancer.

38 . The method of claim 37 , wherein the cancer is a leukemia or lymphoma.

39 . The method of claim 38 , wherein the leukemia or lymphoma is acute myeloid leukemia (AML), chronic myeloid leukemia (CMIL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL).

40 . The method of claim 39 , wherein the non-Hodgkin's lymphoma is a B-cell lymphoma.

41 . The method of claim 40 , wherein the B-cell lymphoma is selected from the group consisting of Burkitt lymphoma, hairy cell lymphoma (HCL), Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B cell lymphoma (DLBCL), B cell chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and pre-B acute lymphoblastic leukemia (pre-B ALL).

42 . The method of claim 37 , wherein the cancer is selected from the group consisting of: multiple myeloma (MM), ovarian cancer, gliomas, colon cancer, breast cancer, bladder cancer, gastric cancer, esophageal cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, mesothelioma, melanoma, glioma, glioblastoma, and pancreatic neuroendocrine tumors.

43 . The method of claim 37 , wherein the cancer is selected from the group consisting of: basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, invasive ductal carcinoma, adenocarcinoma, Merkel cell carcinoma, skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, chrondrosarcoma, myeloma, or multiple myeloma.

44 . The method of claim 36 , wherein the disease or condition is an inflammatory disease, autoimmune disease, allergic inflammatory disease, or neurodegenerative disease.

45 . The method of claim 44 , wherein the disease or condition is rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, psoriatic arthritis, atopic dermatitis, severe asthma, allergic rhinitis and rhinosinusitis, nasal polyposis, atherosclerosis, pulmonary arterial hypertension, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, endometriosis, Alzheimer's disease and related dementias, Parkinson's disease, or Huntington's disease.